BR112019012312A8 - Reagentes para tratamento da distrofia muscular oculofaríngea (opmd) e uso dos mesmos - Google Patents
Reagentes para tratamento da distrofia muscular oculofaríngea (opmd) e uso dos mesmosInfo
- Publication number
- BR112019012312A8 BR112019012312A8 BR112019012312A BR112019012312A BR112019012312A8 BR 112019012312 A8 BR112019012312 A8 BR 112019012312A8 BR 112019012312 A BR112019012312 A BR 112019012312A BR 112019012312 A BR112019012312 A BR 112019012312A BR 112019012312 A8 BR112019012312 A8 BR 112019012312A8
- Authority
- BR
- Brazil
- Prior art keywords
- opmd
- reagents
- treatment
- muscular dystrophy
- oculopharyngeal muscular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434312P | 2016-12-14 | 2016-12-14 | |
| US62/434,312 | 2016-12-14 | ||
| PCT/AU2017/051385 WO2018107228A1 (en) | 2016-12-14 | 2017-12-14 | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112019012312A2 BR112019012312A2 (pt) | 2020-02-11 |
| BR112019012312A8 true BR112019012312A8 (pt) | 2023-02-28 |
Family
ID=62557655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019012312A BR112019012312A8 (pt) | 2016-12-14 | 2017-12-14 | Reagentes para tratamento da distrofia muscular oculofaríngea (opmd) e uso dos mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11142765B2 (enExample) |
| EP (1) | EP3555294A4 (enExample) |
| JP (2) | JP7233149B2 (enExample) |
| KR (2) | KR102495222B1 (enExample) |
| CN (2) | CN118421624A (enExample) |
| AU (2) | AU2017377661B2 (enExample) |
| BR (1) | BR112019012312A8 (enExample) |
| CA (1) | CA3047154A1 (enExample) |
| IL (2) | IL267353B2 (enExample) |
| MX (2) | MX2019007110A (enExample) |
| RU (1) | RU2763319C2 (enExample) |
| WO (1) | WO2018107228A1 (enExample) |
| ZA (1) | ZA202106827B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11142765B2 (en) | 2016-12-14 | 2021-10-12 | Benitec Ip Holdings, Inc. | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
| MX2021004225A (es) * | 2018-10-17 | 2021-05-27 | Benitec Ip Holdings Inc | Metodos para tratar distrofia muscular oculofaringea (dmof). |
| MX2021010412A (es) | 2019-02-28 | 2022-01-24 | Benitec Ip Holdings Inc | Composiciones y metodos para tratar distrofia muscular oculofaringea (opmd). |
| PE20230430A1 (es) * | 2019-12-23 | 2023-03-08 | Versameb Ag | Composiciones y metodos para modular simultaneamente la expresion de genes |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4210737B2 (ja) | 2001-07-12 | 2009-01-21 | ユニバーシティー オブ マサチューセッツ | 遺伝子サイレンシングを仲介する低分子干渉リボ核酸のインビボにおける製造方法 |
| EP1783645A1 (en) | 2005-11-08 | 2007-05-09 | Actigenics | Methods for the identification of microRNA and their applications in research and human health |
| WO2008092935A2 (en) * | 2007-01-31 | 2008-08-07 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and/or increased abiotic stress resistance, and a method for making the same |
| CA2691617C (en) * | 2007-05-31 | 2020-07-21 | University Of Iowa Research Foundation | Reduction of off-target rna interference toxicity |
| WO2010105372A1 (en) * | 2009-03-20 | 2010-09-23 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis c virus expression |
| DK2814514T3 (en) * | 2012-02-16 | 2017-12-18 | Atyr Pharma Inc | Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases |
| WO2014077693A1 (en) * | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
| KR20150103280A (ko) * | 2013-01-08 | 2015-09-09 | 베니텍 바이오파마 리미티드 | 연령-관련 황반 변성 치료 |
| EP3443091A4 (en) * | 2016-04-14 | 2019-11-27 | Benitec Biopharma Limited | REAGENTS FOR THE TREATMENT OF OCULOPHARYNGEAL MUSCLE DYSTROPHY (OPMD) AND USE THEREOF |
| US11142765B2 (en) | 2016-12-14 | 2021-10-12 | Benitec Ip Holdings, Inc. | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
-
2017
- 2017-12-14 US US16/469,992 patent/US11142765B2/en active Active
- 2017-12-14 IL IL267353A patent/IL267353B2/en unknown
- 2017-12-14 AU AU2017377661A patent/AU2017377661B2/en active Active
- 2017-12-14 WO PCT/AU2017/051385 patent/WO2018107228A1/en not_active Ceased
- 2017-12-14 EP EP17882179.9A patent/EP3555294A4/en active Pending
- 2017-12-14 KR KR1020197019981A patent/KR102495222B1/ko active Active
- 2017-12-14 CN CN202410482087.4A patent/CN118421624A/zh active Pending
- 2017-12-14 JP JP2019532105A patent/JP7233149B2/ja active Active
- 2017-12-14 CN CN201780086338.5A patent/CN110382698B/zh active Active
- 2017-12-14 IL IL304674A patent/IL304674B2/en unknown
- 2017-12-14 MX MX2019007110A patent/MX2019007110A/es unknown
- 2017-12-14 CA CA3047154A patent/CA3047154A1/en active Pending
- 2017-12-14 BR BR112019012312A patent/BR112019012312A8/pt active Search and Examination
- 2017-12-14 RU RU2019121950A patent/RU2763319C2/ru active
- 2017-12-14 KR KR1020237003441A patent/KR102667867B1/ko active Active
-
2019
- 2019-06-14 MX MX2024003643A patent/MX2024003643A/es unknown
-
2021
- 2021-09-01 US US17/463,923 patent/US11932852B2/en active Active
- 2021-09-17 ZA ZA2021/06827A patent/ZA202106827B/en unknown
-
2023
- 2023-02-17 JP JP2023023159A patent/JP7431359B2/ja active Active
- 2023-08-28 AU AU2023222827A patent/AU2023222827B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019005548A2 (pt) | tratamento da doença de huntington com aav | |
| CO2020001354A2 (es) | Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia un arni, por ejemplo, un ácido ribonucleico de hebra doble (arnhd), composiciones dirigidas al gen serpinc1 y métodos para usar dicho arni, por ejemplo, arnhd, composiciones para tratar un evento de sangrado en un sujeto que tiene una hemofilia (por ejemplo, con o sin inhibidores). | |
| CY1124292T1 (el) | Συνθεσεις για τροποποιηση της εκφρασης tau | |
| AU2018253578A1 (en) | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) | |
| BR112019012312A8 (pt) | Reagentes para tratamento da distrofia muscular oculofaríngea (opmd) e uso dos mesmos | |
| MX2021006052A (es) | Composiciones de ácido ribonucleico de interferencia (arni) contra el componente del complemento y métodos para su uso. | |
| BR112016002164A2 (pt) | anticorpos de antiactivina a e usos dos mesmos | |
| MX2024008022A (es) | Composiciones y kits para el tratamiento de la hemofilia a o b. | |
| BR112017019054A2 (pt) | métodos para o tratamento de pele | |
| BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
| MX2019008380A (es) | Composiciones de arni contra el componente c5 del complemento y metodos para su uso. | |
| BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
| BR112017021053A2 (pt) | composições de irna de angiopoietina do tipo 3 (angptl3) e métodos de uso do mesmo | |
| BR112023016645A2 (pt) | Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas | |
| BR112022021136A2 (pt) | Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas | |
| MX2018014152A (es) | Composiciones y métodos para tratar la enfermedad de huntington. | |
| BR112017028318A2 (pt) | compostos antibacterianos | |
| BR112014032999A2 (pt) | optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos | |
| BR112012007239A2 (pt) | moléculas de ligação biespecíficas para terapia antiangiogênese | |
| BR112017021967A2 (pt) | composições do fator xii (fator hageman) (f12), kallikrein b, plasma (fator fletcher) 1 (klkb1), e kininogen 1 (kng1) irna e métodos de uso dos mesmos | |
| BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
| BR112022017822A2 (pt) | Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas | |
| BR112022002831A2 (pt) | Formulações anti-c5 de alta concentração | |
| BR112018070249A2 (pt) | sistema promotor de u6 modificada para expressão específica de tecido | |
| BR112019008810A2 (pt) | micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: BENITEC BIOPHARMA PTY LTD (AU) |
|
| B25G | Requested change of headquarter approved |
Owner name: BENITEC BIOPHARMA PTY LTD (AU) |
|
| B25A | Requested transfer of rights approved |
Owner name: BENITEC IP HOLDINGS INC. (US) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |